COVID-19 vaccines developed by Thai researchers undergoing human trials | Inquirer News

COVID-19 vaccines developed by Thai researchers undergoing human trials

/ 03:13 PM July 05, 2021

thai covid-19 vaccines

The Nation/Asia News Network

BANGKOK — Three Covid-19 vaccines are undergoing human trials while more than 20 are in the research phase, the National Research Council of Thailand and National Vaccine Institute said.

The Thai government’s Covid-19 Information Centre announced on Sunday that combined data from the two institutes revealed more than 20 vaccines are being researched and developed in Thailand, while three have started human trials.

Article continues after this advertisement

The three in human trials stage are:

FEATURED STORIES

– ChulaCov19, an MRNA vaccine developed by Chulalongkorn University. It is in the first phase of human trials among 72 candidates. Two doses of the vaccine were given at an interval of 21 days.

– HXP-GPOVac is an inactivated vaccine jointly developed by the Faculty of Tropical Medicine at Mahidol University and the Government Pharmaceutical Organization. It is in the second phase of human trials with 460 candidates. Two doses of the vaccine were injected at an interval of 28 days.

Article continues after this advertisement

– Covigen is a DNA vaccine developed by Bionet Asia and Technovalia, which has started its first phase of human trials among 150 candidates. Two doses of the vaccine were injected at an interval of 28 days.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Covigen, Health, human trials, Thailand

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.